Platelet-vessel wall interactions: implication of 5-hydroxytryptamine. A review.
The evidence for an impact of platelet-derived 5-hydroxytryptamine (5-HT) on local tissue perfusion is reviewed. By interacting with 5-HT2 serotonergic receptors, 5-HT, directly or through amplification, activates platelets, endothelial and vascular smooth muscle cells producing platelet aggregation, vascular permeability increase and large vessel constriction. Pharmacodissection in experimental animals with selective serotonergic 5-HT2 receptor antagonists, e.g. ketanserin, shows that 5-HT largely contributes to the platelet-mediated increase in vascular permeability, to platelet-vessel wall interaction during hemostasis, to cardiopulmonary dysfunction provoked by thromboembolism and to the platelet-mediated inhibition of peripheral collateral circulation. Clinical results obtained with ketanserin further substantiate an involvement of platelet-derived 5-HT in the pathogenesis of impaired tissue perfusion in some cardiovascular conditions.
D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D001808:Blood Vessels / Q000187:drug effects / Q000502:physiology*; D002199:Capillary Permeability; D004727:Endothelium / Q000187:drug effects / Q000502:physiology; D006801:Humans; D066298:In Vitro Techniques; D007650:Ketanserin; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology; D010880:Piperidines / Q000627:therapeutic use; D011985:Receptors, Serotonin / Q000187:drug effects; D012701:Serotonin / Q000494:pharmacology / Q000502:physiology*; D014661:Vasoconstriction
D010880:Piperidines; D011985:Receptors, Serotonin; D012701:Serotonin; D007650:Ketanserin